N
PTGX icon

Nuveen’s Protagonist Therapeutics PTGX Stock Holding History

Nuveen’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
127,914
+2,053
+2% +$182K ﹤0.01% 1383
2025
Q4 		$11M Sell
125,861
-2,523
-2% -$207K ﹤0.01% 1503
2025
Q3 		$8.53M Sell
128,384
-1,127
-0.9% -$64.1K ﹤0.01% 1639
2025
Q2 		$7.16M Sell
129,511
-23,260
-15% -$1.12M ﹤0.01% 1705
2025
Q1 		$7.39M Buy
152,771
+1,574
+1% +$66K ﹤0.01% 1722
2024
Q4 		$5.84M Sell
151,197
-80,877
-35% -$3.53M ﹤0.01% 1908
2024
Q3 		$10.4M Sell
232,074
-141,918
-38% -$5.73M ﹤0.01% 1574
2024
Q2 		$13M Sell
373,992
-304,209
-45% -$8.91M ﹤0.01% 1418
2024
Q1 		$19.6M Buy
678,201
+372,782
+122% +$10.1M 0.01% 1194
2023
Q4 		$7M Sell
305,419
-230,605
-43% -$4.03M ﹤0.01% 1789
2023
Q3 		$8.94M Sell
536,024
-399,937
-43% -$7.76M ﹤0.01% 1544
2023
Q2 		$25.9M Buy
935,961
+107,490
+13% +$2.69M 0.01% 914
2023
Q1 		$19.1M Buy
828,471
+467,757
+130% +$7.86M 0.01% 1080
2022
Q4 		$3.94M Buy
360,714
+22,170
+7% +$187K ﹤0.01% 2052
2022
Q3 		$2.85M Buy
338,544
+572
+0.2% +$5.41K ﹤0.01% 2201
2022
Q2 		$2.67M Buy
337,972
+33,860
+11% +$409K ﹤0.01% 2290
2022
Q1 		$2.35M Buy
304,112
+64,183
+27% +$1.81M ﹤0.01% 2427
2021
Q4 		$1.85M Buy
239,929
+76,843
+47% +$2.43M ﹤0.01% 2599
2021
Q3 		$1.26M Sell
163,086
-3,239
-2% -$138K ﹤0.01% 2894
2021
Q2 		$1.29M Buy
166,325
+21,625
+15% +$714K ﹤0.01% 2911
2021
Q1 		$1.12M Buy
144,700
+32,129
+29% +$813K ﹤0.01% 2853
2020
Q4 		$870K Sell
112,571
-726
-0.6% -$15.6K ﹤0.01% 2853
2020
Q3 		$876K Buy
113,297
+22,525
+25% +$423K ﹤0.01% 2740
2020
Q2 		$701K Sell
90,772
-8,301
-8% -$104K ﹤0.01% 2773
2020
Q1 		$700K Sell
99,073
-95,364
-49% -$715K ﹤0.01% 2656
2019
Q4 		$1.37M Buy
194,437
+43,906
+29% +$436K ﹤0.01% 2578
2019
Q3 		$1.81M Buy
150,531
+111,656
+287% +$1.41M ﹤0.01% 2446
2019
Q2 		$470K Buy
+38,875
New +$430K ﹤0.01% 3026

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Nuveen's PTGX Position: Q1 2026 in Review

Nuveen increased its Protagonist Therapeutics (PTGX) stake by 1.6% in Q1 2026, buying an estimated $182K and bringing the position to 127,914 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Nuveen first reported a position in PTGX in Q2 2019 and has held it in 28 quarters since. The position peaked at $25.9M in Q2 2023. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Nuveen held 127,914 shares of Protagonist Therapeutics worth $13.5M as of Q1 2026.
  • Nuveen bought 2,053 Protagonist Therapeutics shares in Q1 2026, an estimated $182K.
  • Protagonist Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1383 holding.
  • Nuveen first reported a position in Protagonist Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Protagonist Therapeutics position peaked at $25.9M in Q2 2023.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.